family_restroomSpecial Scenario

GLP-1s for Teens

Wegovy and Saxenda are now FDA-approved for adolescents 12 and older with obesity. Here's what the data shows, what changed in pediatric guidelines, and the conversation parents and teens should have together.

The short answer

In December 2022, the FDA expanded the Wegovy (semaglutide) label to include adolescents aged 12 and older with obesity. Saxenda (liraglutide) was approved for the same age group in late 2020. The American Academy of Pediatrics updated its clinical practice guideline in 2023 to recommend evaluating pharmacotherapy for adolescents with obesity, alongside intensive lifestyle treatment. The trial data show meaningful weight loss in adolescents, with side-effect profiles similar to adults. The decision is family-centered and should involve the teen's own voice.

What to know

The pediatric trial that opened the door for Wegovy was STEP TEENS, a 68-week study of about 200 adolescents with obesity randomized to weekly semaglutide 2.4 mg or placebo, both with lifestyle support. The semaglutide group lost about 16% of body weight on average; the placebo group gained slightly. Most secondary endpoints — cardiometabolic markers, quality-of-life scores — improved in the treatment group. Side-effect profile mirrored adult trials, dominated by gastrointestinal symptoms that were usually mild to moderate.

Tirzepatide (Zepbound, Mounjaro) is not yet FDA-approved for adolescents. Pediatric trials are ongoing. As of this writing, only Wegovy and Saxenda carry adolescent indications for chronic weight management. Off-label use of tirzepatide in teens happens but is not endorsed by the label.

The AAP guideline matters here. In 2023, the American Academy of Pediatrics published an updated clinical practice guideline recommending evaluation of pharmacotherapy for adolescents 12 and older with obesity, alongside intensive health behavior and lifestyle treatment. The guideline explicitly moved away from a "watchful waiting" model that had dominated pediatric obesity care for decades. That shift was controversial — some clinicians and family advocates pushed back — but it is the current standard.

Eating disorder screening is non-negotiable. Adolescence is the highest-risk window for eating disorder onset. Most pediatric obesity programs screen with structured questionnaires before starting pharmacotherapy, and many will not initiate a GLP-1 in a teen with active or recently active binge eating, restriction, or purging behaviors. Suicidality and depression history are also part of the screen, given mental health signals occasionally flagged on weight-loss medications.

Conversations with the teen — not just at the teen — matter. Adolescents whose parents drove the decision report worse adherence and worse psychological outcomes than those who were genuinely co-deciders. A few teen-led questions to make space for: how do you feel about being on this medication? what will we tell your friends or not tell them? what do we do if you want to stop?

Practical steps

For families considering it

groups

Pediatric obesity specialist first

Pediatricians comfortable with chronic obesity care are often the right starting point. If your primary pediatrician hasn't prescribed a GLP-1 for a teen before, ask for a referral to a pediatric weight management or endocrinology program.

psychology

Mental health screen up front

An eating disorder and mood screen before starting is standard of care. If your teen has any history of binge eating, restriction, or self-harm, raise it explicitly with the prescriber.

favorite

Center the teen's voice

The data are clearer on outcomes than on long-term adolescent psychology with these drugs. Make the decision with your teen, not for them — including the option to pause if it feels wrong.

Common questions

Common Concerns

Is Wegovy safe for a 12-year-old?expand_more

The STEP TEENS trial supported the FDA's December 2022 approval of Wegovy for adolescents 12 and older with obesity. Side-effect profile in the trial mirrored adults, with gastrointestinal symptoms dominant and most mild to moderate. The boxed warning about thyroid C-cell tumors and the eating-disorder/suicidal-ideation flags apply at any age.

What's the actual BMI threshold for treatment?expand_more

The FDA label uses pediatric BMI definitions of obesity — generally a BMI at or above the 95th percentile for age and sex. The AAP guideline recommends considering pharmacotherapy at this threshold alongside intensive lifestyle treatment. Specific eligibility may also include comorbidities like type 2 diabetes, fatty liver, or sleep apnea.

Will my teen need to take it forever?expand_more

Trials in both adolescents and adults show that stopping a GLP-1 typically leads to regain over the following year. The honest framing is that obesity is a chronic condition and pharmacotherapy is long-term — though some teens may transition off if they reach metabolic health and have strong support structures in place. There is no clean evidence-based answer yet for adolescents specifically.

What about eating disorders?expand_more

Active or recent eating disorder history is generally considered a relative contraindication. The combination of rapid weight loss, reduced appetite, and adolescent identity development can interact in unpredictable ways. Mental health support before, during, and after is part of responsible pediatric prescribing.

Will insurance cover Wegovy for my teen?expand_more

Pediatric coverage varies widely. Some commercial plans cover Wegovy for the adolescent indication; many do not. Medicaid coverage is state-dependent. The Novo Nordisk savings program may apply to commercially insured patients. Cash price remains high without coverage.

Keep exploring

Browse all GLP-1 guides.